Details of the Drug

General Information of Drug (ID: DMFXUT8)

• Drug Name: Oxymetholone
• Synonyms: oxymetholone; Anasterone; 434-07-1; HMS3393H15

Indication

Disease Entry	ICD 11	Status	REF
Aplastic anemia	3A70	Approved	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 332.5
  Topological Polar Surface Area (xlogp); 4.4
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.038 micromolar/kg/day [3]
• Chemical Identifiers:
  Formula: C21H32O3
  IUPAC Name: (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
  Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
  InChI: InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
  InChIKey: ICMWWNHDUZJFDW-DHODBPELSA-N
• Cross-matching ID:
  PubChem CID: 5281034
  ChEBI ID: CHEBI:7864
  CAS Number: 434-07-1
  DrugBank ID: DB06412
  TTD ID: D0Q6NZ
  INTEDE ID: DR1225

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Steroid 5-alpha-reductase 1 (SRD5A1) Main DME	DEOG15F	S5A1_HUMAN	Substrate	[4]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxymetholone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[6]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[7]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Oxymetholone and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[8]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Cannabidiol.	Epileptic encephalopathy [8A62]	[9]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[10]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Oxymetholone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[11]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Oxymetholone and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[12]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[13]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Oxymetholone and Idelalisib.	Mature B-cell leukaemia [2A82]	[14]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Oxymetholone and Carfilzomib.	Multiple myeloma [2A83]	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [3] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [4] Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7.
• [5] Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
• [6] Cerner Multum, Inc. "Australian Product Information.".
• [7] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [8] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [9] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [10] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [11] Canadian Pharmacists Association.
• [12] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [13] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [14] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.